Trial Profile
A Phase II Study of the TRIplet Combination of Dabrafenib, Nivolumab, and Trametinib in Patients With Metastatic Melanoma (TRIDeNT) or Binimetinib, EnCorafenib, and NivolumAb (TRIBECA))
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary) ; Dabrafenib (Primary) ; Encorafenib (Primary) ; Nivolumab (Primary) ; Trametinib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- 05 Dec 2023 Status changed from suspended to active, no longer recruiting.
- 07 Mar 2023 Status changed from active, no longer recruiting to suspended.
- 15 Jun 2022 Status changed from recruiting to active, no longer recruiting.